Lorazepam

Limits on what this shows

• Key negative/null findings: Standard oral tablet or oral solution dosing contains no propylene glycol and carries essentially none of this risk; the label explicitly frames the PG/PEG toxicity warning around "higher than recommended doses" of the injectable product, not routine oral therapy.
• At-risk subgroups: Renal impairment; prolonged or high-cumulative-dose continuous IV infusion (alcohol-withdrawal protocols, status epilepticus, ICU sedation); concomitant use with other propylene-glycol-containing IV drugs (e.g., IV trimethoprim-sulfamethoxazole, as in the Hayman case).
• Counter-evidence on record: DeCarolis DD, et al., "Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium," Pharmacotherapy 2007;27(4):510-8, PMID 17381377, describes a symptom-triggered (as-needed rather than fixed-schedule) IV lorazepam protocol specifically intended to minimize cumulative dosing; by extension this bounds and mitigates propylene glycol exposure, supporting that the risk is dose/duration-dependent and manageable rather than an inherent property of any IV lorazepam exposure.

Regulatory status

FDA injection label, Warnings and Precautions: "There have been reports of possible propylene glycol toxicity (e.g., lactic acidosis, hyperosmolality, hypotension) and possible polyethylene glycol toxicity (e.g., acute tubular necrosis) during administration of lorazepam injection at higher than recommended doses," more likely in renal impairment. The same label's Controlled Clinical Trials adverse-reaction data (Status Epilepticus dose-comparison trial) lists "Acidosis" under the Metabolic and Nutritional category.

Population evidence

Hayman M, et al., "Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole," Pharmacotherapy 2003;23(9):1190-4, PMID 14524651 - case report documenting a marked osmol gap, metabolic acidosis, and renal toxicity attributed to propylene glycol accumulation from concurrent IV lorazepam. Multiple independent case reports indexed in Reactions Weekly document the same lorazepam-propylene-glycol pattern (osmolar-gap metabolic acidosis, lactic acidosis) in 2008 and 2010 (DOIs 10.2165/00128415-200811830-00045 and 10.2165/00128415-201013090-00087). Jahn A, et al., "Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines," Eur J Drug Metab Pharmacokinet 2018;43(4):423-430, PMID 29392569, is an observational study of propylene-glycol-containing IV benzodiazepines (title/bibliographic level access only this session; whether lorazepam specifically made up the full cohort or a subset alongside diazepam could not be confirmed before rate-limiting blocked the individual article page - see Sources). Separately, Pomara N, et al., "Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE epsilon4-negative elderly," PMID 21720235 (2011), found that TOMM40 poly-T genotype (a gene encoding a mitochondrial outer-membrane protein-import channel) modulated the degree of cognitive impairment produced by lorazepam in elderly volunteers; this is a lorazepam-specific, any-route human finding, but its endpoint is cognitive performance, not a direct measurement of mitochondrial structure or respiration.

Mechanism

Propylene glycol (the IV formulation's solvent, not the lorazepam molecule) is metabolized by alcohol and aldehyde dehydrogenase; at high cumulative exposure this pathway saturates, shifts hepatic redox handling, and produces lactic/D-lactic acidosis and hyperosmolality - a formulation-driven metabolic burden. The TOMM40 finding suggests a separate, molecule-level pathway by which lorazepam's CNS effects interact with mitochondrial protein-import capacity, though the mechanism linking genotype to cognitive toxicity is not fully characterized.

Counter-evidence held on record

This is an excipient/formulation toxicity of the injectable product at supratherapeutic or prolonged dosing, not a property of oral lorazepam or of standard therapeutic dosing, and it is not a nutrient deficiency. Supplementation is not relevant; the corrective action is dose/duration limitation, renal-function monitoring, and osmolar-gap surveillance under clinical supervision.

Limits on what this shows

• Why no grade: Both conditions for ungraded are now met with materially higher confidence than in the prior review. No Tier A/B/C evidence supports a grade, and no circulating consumer claim exists to rebut as white. The two studies that surface for "lorazepam oxidative stress" were actually retrieved and read this session (not merely blocked), and both were affirmatively excluded on cohort grounds rather than left unexamined.

Tooling disclosure

This repair session's PubMed search-listing query for "lorazepam oxidative stress" was reachable and returned 4 results: Tsiakitzis et al., PMID 19863055 (J Med Chem, 2009) and Theodosis-Nobelos et al., PMID 31505754 (Molecules, 2019), both titles suggestive of a direct match; plus a naproxen-induced-methemoglobinemia case report (PMID 24856747) and an oral-solution repackaging stability study (PMID 41112338), both unrelated to lorazepam's own biological oxidative-stress profile. Because PubMed's individual article pages and Europe PMC and Semantic Scholar's search endpoints were rate-limited (HTTP 429) on every attempt this session, the two candidate titles were resolved instead through OpenAlex's per-DOI and per-PMID lookup endpoints, which stayed reachable throughout even while OpenAlex's own search endpoint was blocked. Those records show that Tsiakitzis 2009 designed novel hybrid compounds pairing GABA esterified with lorazepam and amidated with a vitamin-E-like (tetramethylchroman-carboxylic acid) or BHT-like (3,5-di-tert-butyl-4-hydroxybenzoic acid) antioxidant group, and reports lipid-peroxidation inhibition (IC50 1.1-24 microM) for those new compounds, not for unmodified lorazepam. Theodosis-Nobelos 2019 similarly conjugated lorazepam with a hydroxyphenyl-acrylic-acid antioxidant/anti-inflammatory moiety and measured lipid-peroxidation inhibition and radical-scavenging activity in the resulting derivatives, tested in rats, again not in unmodified lorazepam. Neither study passes the cohort test for lorazepam itself, so neither can support a grade at any tier. A repeated Crossref bibliographic search for "lorazepam oxidative stress" again returned only two unrelated book chapters on oxidative stress in aging and inflammation, matching the original review's finding. A follow-up class-level query ("benzodiazepine oxidative stress"; "diazepam oxidative stress rat"), intended to check whether another benzodiazepine has Tier C-eligible data the way flunitrazepam does for Gut microbiome risk, was attempted via both PubMed and Crossref but was blocked by rate-limiting before returning results, so a class-level yellow grade could not be ruled in or confirmed this session. No circulating consumer claim about lorazepam and oxidative stress or antioxidant depletion was found on drugs.com. This is a firmer ungraded finding than the prior review's: the apparent hits were retrieved, read, and excluded on a stated rule, rather than the category being blocked outright. A future revision could still attempt the class-level benzodiazepine query if Europe PMC, Semantic Scholar, or OpenAlex's search endpoint becomes reachable.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met, now on two independently corroborating channels. A PubMed search-listing query for "lorazepam copper" returned a cleanly loaded page with no matching article content, consistent with the confirmed-zero-result pattern seen elsewhere in this review (for example, lorazepam plus anemia/hemoglobin and lorazepam plus gut microbiota, both of which displayed explicit "no results" states). No copper-related claim about lorazepam appeared in the label, in this search, or among the standard CNS-drug depletion claims (melatonin, B12, magnesium, CoQ10) tested elsewhere in this dossier.

Tooling disclosure

The Crossref corroboration query for "lorazepam copper" that could not be completed in the original review was repeated in this repair session and returned cleanly (no rate-limit block): only unrelated pharmacopeia and formulary reference entries (USP monographs, Royal Pharmaceutical Society BNF/BNFc entries, a Springer drug-reference chapter), none touching copper, ceruloplasmin, or trace-mineral status. This matches and corroborates the original PubMed clean-zero finding rather than contradicting it, and closes the corroboration gap noted in the prior review. Europe PMC's REST API, the Semantic Scholar API, and OpenAlex's search endpoint were each blocked by proxy-level rate-limiting (HTTP 429) on every attempt made this repair session, including after cooldown waits up to 90 seconds; no candidate article surfaced on any reachable channel to check further via OpenAlex's per-DOI/per-PMID lookup endpoints, which otherwise remained reachable throughout. This category is now treated as a genuine, two-channel-corroborated literature gap rather than a single-source or tooling-limited result.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met once the confounded co-occurrences below are set aside per Hard Rule 6 (confounding by indication) and Hard Rules 2/3 (an outcome finding is not a nutrient-status finding). A PubMed search for "lorazepam iron" returned no interventional or mechanistic study of lorazepam's effect on iron status; the only co-occurrences were: Zingela Z, et al., PMID 35756352 (2022), reporting that 45.5% of catatonia patients had low average iron levels at presentation, before or alongside treatment with lorazepam and/or electroconvulsive therapy - this describes the catatonic condition's own association with low iron, not a treatment-emergent effect of lorazepam, and is exactly the confounding-by-indication pattern Hard Rule 6 requires excluding from a drug-attribution grade. Chandra PS, et al., PMID 26702173 (2015), similarly reports minor serum iron and transferrin-saturation changes alongside diagnostic "lorazepam challenge" testing in pediatric catatonia, again a co-occurrence within an already iron-atypical population rather than a measurement of lorazepam's effect on iron. Separately, the Oxygen delivery/utilization entry above documents trial-level hypochromic anemia for the injectable formulation, but per Hard Rules 2/3 this outcome-level blood-count finding is not reused here because iron status itself (ferritin, serum iron, TIBC) was not measured in that trial data - see the Overlap map. No circulating claim specifically linking lorazepam to iron depletion was found on drugs.com, the one consumer source accessible this session.

Tooling disclosure

The PubMed and catatonia-literature searches for this category were genuinely accessible and returned real (if confounded) content rather than blocked responses, so the absence of a direct lorazepam-iron mechanism is treated as a real literature gap, not a pure tooling failure. Broader consumer-claim search engines (Google, Bing, DuckDuckGo) and the WebSearch tool were not reachable this session (see Sources access note), so a fringe consumer claim outside the channels checked here cannot be fully ruled out.

Limits on what this shows

• Key negative/null findings: None specific to lorazepam, precisely because no drug-specific study exists.
• At-risk subgroups: Cannot be specified without drug-specific data.
• Counter-evidence on record: This is explicitly labeled class extrapolation per Step 4/7 of the governing protocol: the class member with data (flunitrazepam) is metabolically distinct from lorazepam in exactly the dimension (CYP oxidation vs. glucuronidation) this dossier is asked to scrutinize, so the extrapolation is weaker than a same-clearance-pathway comparison would be.

Regulatory status

Not addressed in the FDA label.

Population evidence

A direct PubMed search for "lorazepam gut microbiota" returned zero results (the search page loaded cleanly and displayed no matching content, consistent with a genuine null result rather than a block). Class-level (Tier C) evidence exists for a different benzodiazepine: Lin W, Li K, Qin Y, Han X, Chen X, Ren Y, "Flunitrazepam induces neurotoxicity in zebrafish through microbiota-gut-brain axis," PMID 37260381 (2023), found that flunitrazepam disrupted gut microbiota balance and increased pathogenic bacteria (Paracoccus, Aeromonas) with resulting intestinal damage in zebrafish. Lorazepam was not in this cohort.

Mechanism

Plausible but unconfirmed for lorazepam: GABA-A receptors are expressed on enteric neurons and gut-associated immune tissue, and both lorazepam and flunitrazepam are GABA-A receptor positive allosteric modulators, so a class-level gut-brain-axis effect is biologically conceivable. However, flunitrazepam is cleared by hepatic CYP-mediated N-demethylation and hydroxylation, while lorazepam is cleared by direct glucuronidation with no CYP step - a real metabolic difference that weakens, rather than strengthens, the read-across, since the zebrafish study did not isolate whether the gut effect traced to the parent drug, a CYP-generated metabolite, or a receptor-level effect common to both.

Counter-evidence held on record

This entry must not be presented to a reader as "lorazepam disrupts your gut microbiome" - it is a distant class read-across from a zebrafish study of a different, metabolically distinct benzodiazepine, not a lorazepam-specific finding.

Limits on what this shows

• Key negative/null findings: As with Mitochondrial burden, oral lorazepam carries no propylene glycol and no corresponding ATP-production risk; the label's "Acidosis" listing is specific to the Status Epilepticus (IV) trial population.
• At-risk subgroups: Same as Mitochondrial burden: renal impairment, prolonged/high-cumulative-dose IV infusion, concomitant propylene-glycol-containing drugs.
• Counter-evidence on record: Same DeCarolis 2007 symptom-triggered dosing protocol cited under Mitochondrial burden; no case report or trial finding identified this session reported lactic acidosis at standard, non-prolonged, non-high-dose IV lorazepam exposure.

Regulatory status

Same FDA injection label sources as Mitochondrial burden: the Warnings and Precautions propylene-glycol-toxicity statement (lactic acidosis, hyperosmolality, hypotension) and the Controlled Clinical Trials "Acidosis" entry under Metabolic and Nutritional adverse reactions in the Status Epilepticus dose-comparison trial.

Population evidence

Hayman 2003 (PMID 14524651) and the 2008/2010 Reactions Weekly case reports cited under Mitochondrial burden above measured and reported lactic acidosis and osmolar gap directly - lactate elevation is itself the biochemical marker of impaired aerobic (oxidative-phosphorylation-linked) ATP synthesis forcing a shift toward anaerobic glycolysis. See Sources for full citations; not repeated here to avoid duplicate listing.

Mechanism

When propylene glycol metabolism saturates hepatic oxidative capacity, pyruvate is diverted toward lactate rather than entering the mitochondrial tricarboxylic acid cycle, directly reducing oxidative-phosphorylation-linked ATP output and forcing compensatory anaerobic glycolysis - the same underlying excipient-toxicity mechanism as Mitochondrial burden, viewed through its energetic endpoint rather than its structural one (see Overlap map).

Counter-evidence held on record

This entry and Mitochondrial burden are not independent confirmations of each other; they report the same underlying propylene-glycol-toxicity mechanism and largely the same sources, viewed as structural burden versus energetic (ATP/lactate) output. See the Overlap map. This is not a deficiency correctable by supplementation.

Limits on what this shows

• Key negative/null findings: The oral tablet label does not list hypochromic anemia at all; the finding is specific to controlled trials of the injectable formulation, and its absence from the oral safety data is itself informative.
• At-risk subgroups: Patients receiving IV lorazepam in critical-care, status-epilepticus, or high-dose/prolonged-infusion contexts, consistent with the population underlying the label's own trial data.
• Counter-evidence on record: No frequency/incidence rate is given anywhere in the label for hypochromic anemia, leukocytosis, or thrombocythemia; the label reports these as a categorical list from controlled trials without a denominator, which bounds this entry to orange rather than red, and no primary literature source with a measured incidence rate was accessible this session to strengthen it further.

Regulatory status

FDA injection label, Adverse Reactions, Controlled Clinical Trials, Hemic and lymphatic system: hypochromic anemia, leukocytosis, thrombocythemia. Postmarketing Reports separately lists thrombocytopenia and coagulation disorder. The oral tablet label separately notes that "some patients on lorazepam have developed leukopenia" with long-term therapy, and elevations in LDH, with periodic blood counts recommended for long-term use - a distinct, oral-specific signal, not double-counted here.

Population evidence

This entry rests on the injection label's own controlled-trial dataset, drawn substantially from status-epilepticus and critical-care dosing contexts (the label's own Status Epilepticus dosing section appears adjacent to this adverse-reaction data). No incidence rate is reported in the categorical adverse-reaction listing. Drugs.com's aggregated, FDA-label-sourced side-effect compendium corroborates hypochromic anemia specifically for parenteral lorazepam (Tier D corroboration only; not used as independent support for the grade, which rests on the Tier A label itself).

Mechanism

Not established or named in the label; no hemolysis-specific, iron-status, or bone-marrow-suppression mechanism is documented. This is a genuinely unexplained trial-level hematologic signal, reported as a category rather than a mechanism.

Counter-evidence held on record

Hypochromic anemia here is a red-cell morphology finding reported in the injectable formulation's trial safety data. It must not be presented as evidence that lorazepam depletes iron - iron status itself (ferritin, serum iron, TIBC) was not measured in this trial data, and no causal mechanism is established. See Iron below and the Overlap map for why this finding is not reused to grade Iron.